Endo International PLC (LTS:0Y5F)
$ 0.0006 0 (0%) Market Cap: 141,000.00 Enterprise Value: -772.69 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 50/100

Endo International PLC at JPMorgan Global High Yield & Leveraged Finance Conference (Virtual) Transcript

Mar 01, 2021 / 02:15PM GMT
Release Date Price: $7.67 (-4.72%)
David Breadon Common
JPMorgan Chase & Co, Research Division - MD, Head of North American High Yield Credit Research and Senior Analyst

Good morning, again, everybody. I'm David Common, and I cover all of health care for the non-investment-grade space at JPMorgan. We're kicking off today with Endo Pharmaceuticals. We're very happy to have Mark Bradley and Laure Park. And I want to remind you that we do have this ask a question feature, which I think most investors are familiar with.

So again, don't be shy. But I actually have about a dozen questions. We're not going to go through slides. I'm just going to launch into them. And hopefully, I will sort of preempt many of the things that are on your mind. (Operator Instructions) So Mark, I guess, where I'd like to start to sort of level set people because, as you know, we're not as expert as really your typical equity investors, I would say.

Can we just review that BioSpecifics acquisition? Tell us how long you were thinking about doing that deal? Why it came together last year? And then the strategic and financial implications for you.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot